Holen Sie sich die Stockscreener-App
3.12
0.34%
-0.0107
Handel nachbörslich:
3.12
Schlusskurs vom Vortag:
$3.1307
Offen:
$3.12
24-Stunden-Volumen:
6,492
Relative Volume:
0.66
Marktkapitalisierung:
$110.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+3.65%
1M Leistung:
+24.30%
6M Leistung:
+6.12%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.0969
$3.14
1-Wochen-Bereich:
$2.78
$3.14
52-Wochen-Spanne:
$2.20
$3.79
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Firmenname
Eupraxia Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie EPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| EPRX | 3.12 | 110.43M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Rodman & Renshaw - Defense World
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Eupraxia Pharmaceuticals files report with SEC - Investing.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Rating Increased to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Rodman & Renshaw rates Eupraxia stock Buy on 'groundbreaking delivery tech' - Investing.com Canada
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting - BioSpace
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Rodman & Renshaw - MarketBeat
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 - PR Newswire
Eupraxia Pharmaceuticals reports regulatory update - Investing.com
Newswire - KelownaNow
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - Quantisnow
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - Quantisnow
Finansavisen - Finansavisen
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 5.4%What's Next? - MarketBeat
Troutman Pepper Advises Eupraxia Pharmaceuticals in Closing of a Non-Brokered Private Placement - Troutman Pepper
Eupraxia Pharmaceuticals Shares Rise After Completing Private Placement - MarketWatch
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - Quantisnow
Microstrategy Cl A (MSTR-Q) QuotePress Release - The Globe and Mail
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Eupraxia Pharmaceuticals Inc (EPRX-T) QuotePress Release - The Globe and Mail
Fennec Pharmaceuticals Inc. - Baystreet.ca
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 - Quantisnow
Eupraxia reports Phase 2b trial success for osteoarthritis treatment - Investing.com India
Eupraxia reports Phase 2b trial success for osteoarthritis treatment By Investing.com - Investing.com Canada
Health Rounds: Steroid injection relieves knee arthritis pain for months - Reuters
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis - StockTitan
Stocks In Play: Eupraxia Pharmaceuticals Inc. - Barchart
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 3.4%What's Next? - MarketBeat
Eupraxia Pharmaceuticals reports to SEC on latest developments - Investing.com India
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results - Barchart
Eupraxia Pharmaceuticals reports to SEC on latest developments By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals Highlights Innovation at UEG Week 2024 - TipRanks
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 - PR Newswire
EPRX stock touches 52-week low at $2.34 amid market challenges - Investing.com Australia
EPRX stock touches 52-week low at $2.34 amid market challenges By Investing.com - Investing.com South Africa
eupraxia pharmaceuticals inc. Earnings dates - RTTNews
Eupraxia Pharmaceuticals expands leadership team - Investing.com India
Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com Canada
Eupraxia Pharmaceuticals expands leadership team By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals Enhances Leadership Team - TipRanks
Eupraxia Pharmaceuticals Strengthens Senior Management Team – Company Announcement - Financial Times
Mutual of America Capital Management LLC Sells 1,218 Shares of Euronet Worldwide, Inc. (NASDAQ:EEFT) - Defense World
Itau Unibanco Holding S.A. Buys New Position in Edwards Lifesciences Co. (NYSE:EW) - Defense World
Amalgamated Bank Grows Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Eupraxia Pharmaceuticals Showcases Innovative Therapy at ISDE Congress - TipRanks
Eupraxia Pharmaceuticals to present at ISDE Congress for Esophageal Diseases - TipRanks
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases - Kilgore News Herald
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 4.8% - MarketBeat
Finanzdaten der Eupraxia Pharmaceuticals Inc-Aktie (EPRX)
Es liegen keine Finanzdaten für Eupraxia Pharmaceuticals Inc (EPRX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):